Malathi Hari

发表

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

T. Fojo, F. Loganzo, M. Poruchynsky, 2004, Molecular cancer therapeutics.

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

T. Fojo, R. Andersen, J. Nieman, 2003, Cancer research.

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

J. Snyder, J. Nettles, F. Loganzo, 2006, Molecular Cancer Therapeutics.

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.

Hailing Yang, F. Cabral, Malathi Hari, 2003, Cell motility and the cytoskeleton.

Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models

Deepak Sampath, Carol Rios, D. Sampath, 2006, Clinical Cancer Research.

Random Mutagenesis of β-Tubulin Defines a Set of Dispersed Mutations That Confer Paclitaxel Resistance

Shanghua Yin, F. Cabral, Malathi Hari, 2012, Pharmaceutical Research.

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.

Yaqing Wang, F. Cabral, Malathi Hari, 2003, Molecular cancer therapeutics.

Paclitaxel resistance by random mutagenesis of α‐tubulin

Shanghua Yin, F. Cabral, Malathi Hari, 2013, Cytoskeleton.

Random Mutagenesis of β-Tubulin Defines a Set of Dispersed Mutations That Confer Paclitaxel Resistance

Shanghua Yin, F. Cabral, Malathi Hari, 2012, Pharmaceutical Research.

Two Photoaffinity Analogues of the Tripeptide, Hemiasterlin, Exclusively Label α-Tubulin

F. Loganzo, G. Krishnamurthy, A. Zask, 2005 .

B480 Proteomic Alterations Caused by Treatment with Velcade, Doxorubicin, and Dexamethasone in Myeloma

A. Nesvizhskii, A. Jakubowiak, A. Sreekumar, 2009 .

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar®) Correlates with Response to Therapy

M. Kaminski, A. Jakubowiak, S. Mineishi, 2008 .

Pre-clinical evaluation of bortezomib, doxorubicin, dexamethasone, and lenalidomide in multiple myeloma (MM)

A. Jakubowiak, M. Soengas, D. Lebovic, 2008 .